EUCTR2017-003739-12-IT进行中（未招募）1 期
Preoperative Nivolumab in patients with locally advanced colon cancer (T3 or T4): a window-of-opportunity study - NICOLE - NIvolumab in locally advanced COLon cancEr
SOCIETà CAMPANA DI IMMUNOTERAPIA ONCOLOGICA0 个研究点目标入组 22 人开始时间: 2021年1月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Patients diagnosed with histologically confirmed adenocarcinoma of colon with staging of locally advanced (T3 or T4)
- •2)No prior treatments (chemotherapy, radiation or surgery) for colon cancer
- •3)Either sex aged = 18 years
- •4)Colon lesion determined and measured preoperatively by either spiral or multidetector CT scan
- •5)ECOG Performance Status =1 at study entry
- •6)Adequate bone marrow haematological function: absolute neutrophil count (ANC) = 1.5 x 109/L AND platelet count = 100 x 109/L AND haemoglobin = 9 g/dL
- •7)Adequate liver function: total bilirubin = 1.5 x upper limit of normal (ULN) AND aspartate aminotransferase (AST)/alanine aminotransferase (ALT) = 2.5 X ULN
- •8)Adequate renal function: serum creatinine = 1.5 mg/dL OR creatinine clearance = 60 mL/min in males and =50 mL/min in females (calculated according to Cockroft-Gault formula)
- •9)Serum calcium levels, international normalised ratio (INR) and partial thromboplastin time were within normal limits
- •10)Female subjects of childbearing potential must have a negative urine pregnancy test result at baseline and practice a reliable method of contraception throughout the study
- •11)Availability of tumor tissue from basal biopsy for immunoscore and biomarker analysis.
- •12)Ability to understand study-related patient information and provision of written informed consent for participation in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 11
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 11
排除标准
- •1)Evidence of metastatic disease
- •2)Prior malignancy within the prior 5 years. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer
- •3)Subjects with active, known or suspected autoimmune disease
- •4)Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatment
- •5)Prior treatment with an anti-PD-1, anti-Programmed Death 1 ligand (PD-L1), anti-PD-L2, or anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) antibody
- •6)Female subjects who are pregnant (positive urine pregnancy test), breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control
- •7)Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator’s opinion makes it undesirable for the patient to participate in the study, or which would jeopardize compliance with the protocol, or would interfere with the results of the study
- •8)Patients with a history of cardiovascular or interstitial lung disease and evidence or risk of retinal vein occlusion or central serous retinopathy
- •9)Inability to regularly access center facilities for logistical or other reasons
- •10)History of poor co-operation, non-compliance with medical treatment, or unreliability
- •11)Participation in any interventional drug or medical device study within 30 days prior to treatment start
- •12)Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C (HCV antibody) with virus ribonucleic acid indicating acute or chronic infection;
- •13)Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
研究者
相似试验
已完成
2 期
Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity StudyColon Cancer Stage II/IIINCT04123925National Cancer Institute, Naples22
进行中（未招募）
2 期
Preoperative Nivolumab (Opdivo) to evaluate pathologic response in patients with stage I non-small cell lung cancer: a phase 2 trialJPRN-jRCT2061180016Okada Morihito50
进行中（未招募）
2 期
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLCNon-Small Cell Lung CancerNCT02259621Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins39
已完成
2 期
Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHNHead and Neck Squamous Cell CarcinomaHead and Neck CancerHead and Neck Cancer MetastaticNCT03878979Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins26
已完成
2 期
Phase II study of Nivolumab in patients with relapsed/refractory hematologic malignanciesmalignant lymphoma, myelodysplastic syndromesJPRN-UMIN000033794ational Cancer Center Hospital East40